Grapefruit juice can significantly increase blood levels of certain anti-arrhythmic drugs by inhibiting their metabolism, potentially leading to enhanced therapeutic effects or toxicity.
Interaction affects CYP3A4-metabolized anti-arrhythmics (e.g., amiodarone, dronedarone, verapamil); not all class members are impacted equally.
Even small amounts of grapefruit juice (e.g., 8 oz) can inhibit CYP3A4 for up to 24 hours.
Consult prescriber before consuming grapefruit; therapeutic drug monitoring recommended for high-risk patients.
No interaction with non-CYP3A4 substrates like lidocaine or beta-blockers (e.g., metoprolol).
Grapefruit juice contains furanocoumarins that inhibit the cytochrome P450 3A4 (CYP3A4) enzyme in the intestines and liver, reducing the first-pass metabolism of CYP3A4 substrate anti-arrhythmics such as amiodarone, dronedarone, and verapamil, resulting in elevated plasma concentrations.
Increased risk of adverse effects including QT prolongation, arrhythmias, bradycardia, hypotension, and potential proarrhythmic events; severity varies by specific drug (e.g., major interaction with amiodarone).
Advise patients to avoid grapefruit juice and products containing it while on affected anti-arrhythmics; monitor drug levels and ECG if interaction occurs; consider alternative citrus juices like orange juice.
Was this helpful?
The content on SafeTo is for informational purposes only and does not constitute medical, veterinary, or professional advice. Always consult with a qualified professional for specific concerns.
